LT 6001
Alternative Names: LT-6001Latest Information Update: 31 Mar 2023
At a glance
- Originator Lumosa Therapeutics
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Neurological disorders
Most Recent Events
- 29 Mar 2023 LT 6001 is available for licensing as of 29 Mar 2023.
- 29 Mar 2023 Preclinical trials in Neurological disorders in Taiwan (unspecified route) (Lumosa Therapeutics pipeline, March 2023)